000128685 001__ 128685
000128685 005__ 20240228145546.0
000128685 0247_ $$2doi$$a10.3174/ajnr.A5313
000128685 0247_ $$2pmid$$apmid:28798218
000128685 0247_ $$2ISSN$$a0195-6108
000128685 0247_ $$2ISSN$$a1936-959X
000128685 0247_ $$2altmetric$$aaltmetric:23666742
000128685 037__ $$aDKFZ-2017-04700
000128685 041__ $$aeng
000128685 082__ $$a610
000128685 1001_ $$00000-0001-8699-3506$$aKeil, V. C.$$b0
000128685 245__ $$aImaging Biomarkers for Adult Medulloblastomas: Genetic Entities May Be Identified by Their MR Imaging Radiophenotype.
000128685 260__ $$aOak Brook, Ill.$$bSoc.$$c2017
000128685 3367_ $$2DRIVER$$aarticle
000128685 3367_ $$2DataCite$$aOutput Types/Journal article
000128685 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1510738742_15347
000128685 3367_ $$2BibTeX$$aARTICLE
000128685 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000128685 3367_ $$00$$2EndNote$$aJournal Article
000128685 520__ $$aThe occurrence of medulloblastomas in adults is rare; nevertheless, these tumors can be subdivided into genetic and histologic entities each having distinct prognoses. This study aimed to identify MR imaging biomarkers to classify these entities and to uncover differences in MR imaging biomarkers identified in pediatric medulloblastomas.Eligible preoperative MRIs from 28 patients (11 women; 22-53 years of age) of the Multicenter Pilot-study for the Therapy of Medulloblastoma of Adults (NOA-7) cohort were assessed by 3 experienced neuroradiologists. Lesions and perifocal edema were volumetrized and multiparametrically evaluated for classic morphologic characteristics, location, hydrocephalus, and Chang criteria. To identify MR imaging biomarkers, we correlated genetic entities sonic hedgehog (SHH) TP53 wild type, wingless (WNT), and non-WNT/non-SHH medulloblastomas (in adults, Group 4), and histologic entities were correlated with the imaging criteria. These MR imaging biomarkers were compared with corresponding data from a pediatric study.There were 19 SHH TP53 wild type (69%), 4 WNT-activated (14%), and 5 Group 4 (17%) medulloblastomas. Six potential MR imaging biomarkers were identified, 3 of which, hydrocephalus (P = .03), intraventricular macrometastases (P = .02), and hemorrhage (P = .04), when combined, could identify WNT medulloblastoma with 100% sensitivity and 88.3% specificity (95% CI, 39.8%-100.0% and 62.6%-95.3%). WNT-activated nuclear β-catenin accumulating medulloblastomas were smaller than the other entities (95% CI, 5.2-22.3 cm(3) versus 35.1-47.6 cm(3); P = .03). Hemorrhage was exclusively present in non-WNT/non-SHH medulloblastomas (P = .04; n = 2/5). MR imaging biomarkers were all discordant from those identified in the pediatric cohort. Desmoplastic/nodular medulloblastomas were more rarely in contact with the fourth ventricle (4/15 versus 7/13; P = .04).MR imaging biomarkers can help distinguish histologic and genetic medulloblastoma entities in adults and appear to be different from those identified in children.
000128685 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000128685 588__ $$aDataset connected to CrossRef, PubMed,
000128685 7001_ $$00000-0002-3544-319X$$aWarmuth-Metz, M.$$b1
000128685 7001_ $$00000-0002-6298-8224$$aReh, C.$$b2
000128685 7001_ $$00000-0002-5819-0308$$aEnkirch, S. J.$$b3
000128685 7001_ $$00000-0003-1085-1442$$aReinert, C.$$b4
000128685 7001_ $$00000-0002-3336-157X$$aBeier, D.$$b5
000128685 7001_ $$00000-0002-2036-5141$$aJones, D. T. W.$$b6
000128685 7001_ $$00000-0002-9252-8923$$aPietsch, T.$$b7
000128685 7001_ $$00000-0003-4264-0121$$aSchild, H. H.$$b8
000128685 7001_ $$00000-0002-8392-9004$$aHattingen, E.$$b9
000128685 7001_ $$00000-0003-3894-5053$$aHau, P.$$b10
000128685 773__ $$0PERI:(DE-600)2025541-X$$a10.3174/ajnr.A5313$$gVol. 38, no. 10, p. 1892 - 1898$$n10$$p1892 - 1898$$tAmerican journal of neuroradiology$$v38$$x1936-959X$$y2017
000128685 909CO $$ooai:inrepo02.dkfz.de:128685$$pVDB
000128685 9101_ $$0I:(DE-588b)2036810-0$$60000-0002-2036-5141$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000128685 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000128685 9141_ $$y2017
000128685 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bAM J NEURORADIOL : 2015
000128685 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000128685 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000128685 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000128685 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000128685 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000128685 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000128685 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000128685 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000128685 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000128685 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000128685 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lPädiatrische Neuroonkologie$$x0
000128685 980__ $$ajournal
000128685 980__ $$aVDB
000128685 980__ $$aI:(DE-He78)B062-20160331
000128685 980__ $$aUNRESTRICTED